Industry experts from Marsh McLennan Agency (MMA) discuss how organizations can leverage innovative tools, such as biosimilar-first contracts, to effectively reduce pharmaceutical expenses without compromising care.



Related insights

Replay

Replay: From cost crunch to culture boost: Transforming employee benefits for the future

Healthcare costs are rising at their fastest pace in a decade while employee engagement sits at multi-year lows, forcing employers to find practical ways to control spending without hurting workforce well‑being. Watch our webinar replay to learn innovative benefits strategies and alternative funding models that help manage costs without ...

Whitepapers

Senior care risk and insurance report

In 2026, aging populations, technological change, and economic pressures make innovative risk management essential to senior care resilience and financial health.

Case Studies

R.W. Dunteman saves $3K per employee with IRTBA association health plan

Learn how Marsh McLennan Agency helped construction company R.W. Dunteman save $3K per employee with IRTBA association health plan.

More Insights